Introduction {#S5}
============

The adult human heart cannot effectively regenerate after injury. Therefore, new therapeutic strategies to attain cardiac repair are extensively explored. A promising approach to regenerate the injured heart is intra-cardiac transplantation of stem or progenitor cells. Its success, however, is impaired by poor donor cell survival and by the limited capacity of the transplanted cells to differentiate into functional cardiomyocytes in the acceptor organ \[[@R1]\]. A strategy to overcome the named problems would be the induction of cardiomyogenic function in donor cells prior to transplantation (e.g. \[[@R2]-[@R4]\]). Besides attempts to drive the differentiation of induced pluripotent stem cells \[[@R5]\] into cardiomyocytes (e.g. \[[@R6]\]), synthetic small molecules were recently identified, which exhibit remarkable cardiomyogenic effects on various types of stem cells. For example, sulfonyl hydrazone type small molecules were reported to induce the expression of cardiac proteins in different embryonic and adult stem cell types \[[@R7]\]. Noteworthy, these authors also found that sulfonyl hydrazone treatment of the donor cells prior to transplantation improved myocardial repair in a rat model. This highlights the significant therapeutic potential of cardiomyogenic small molecules to support myocardial regeneration. Another also conceivable strategy would be the promotion of cardiac repair by the induction of cardiomyogenic differentiation in residual cardiovascular progenitor cells in situ by small molecules \[[@R8]\]. Besides the sulfonyl hydrazones, the "cardiogenols" \[[@R9]\] represent another promising group of cardiomyogenic small molecules. Thus, the most active compound among the cardiogenols, the diaminopyrimidine cardiogenol C (CgC), induced P19 embryonic carcinoma cells and R1 mouse embryonic stem cells to differentiate into spontaneously beating cardiomyocytes \[[@R9]\]. This study suggested that CgC exerts a cardiomyogenic effect on embryonic stem cells.

The first aim of the present study was to assess whether, besides acting on pluripotent embryonic stem cells, CgC also exerts cardiomyogenic effects on already lineage-committed progenitor cell types with a limited degree of plasticity. Secondly, for the first time, we tested if this small molecule induces cardiac functional properties in cells in addition to cardiac marker up-regulation. Finally, structural derivatives of CgC were studied for cardiomyogenic activity. We report that CgC treatment induces cardiomyogenic function in lineage-committed progenitor cells.

Materials and Methods {#S6}
=====================

Cells and culture conditions {#S7}
----------------------------

P19 mouse embryonic carcinoma cells (American Type Culture Collection, ATCC) were cultured in minimum essential medium (MEM)-alpha (Sigma-Aldrich) containing 4 mM L-glutamine, 50 U/ml penicillin, 50μg/ml streptomycin, 7.5% new born calf serum, and 2.5% fetal bovine serum at 37 °C in 5% CO~2~. At the begin of an experiment (CgC treatment), control and treated cells were transferred to an "induction medium" (MEM-alpha, 5% fetal bovine serum, 4 mM L-glutamine, 50 U/ml penicillin, 50μg/ml streptomycin) as in \[[@R9]\].

C2C12 mouse skeletal myoblasts (ATCC) were cultured in growth medium consisting of Dulbecco's modified Eagle's medium (DMEM, Life Technologies) containing 4.5 g/l glucose, 4 mM L-glutamine, 50 U/ml penicillin, 50μg/ml streptomycin, and 20% fetal calf serum. The cells were incubated at 37 °C and 5% CO~2~, and at about 50--70% cell confluence (before the emersion of any multi-nucleated myotubes) differentiation was induced by serum reduction. Therefore, myoblasts were incubated in differentiation medium which was identical to the growth medium, except that it contained 2% horse serum instead of 20% fetal calf serum. CgC and other small molecule compounds to be tested were always added at the same time as differentiation was induced.

Human primary skeletal myoblasts were isolated from skeletal muscle biopsies of healthy individuals as in \[[@R10]\]. The procedure was approved by the ethic committee of the Medical University of Vienna (L. Weigl; General Hospital, Vienna, Austria). The myoblasts were kept in growth medium consisting of Ham's F-12 medium (PAA laboratories), 15% fetal calf serum, 10 ng/ml epidermal growth factor, 200 ng/ml insulin, 400 ng/ml dexamethasone, 0.5 mg/ml fetuin, 0.5 mg/ml bovine serum albumin, 7 mM glucose, 4 mM L-glutamine, 200 units/ml penicillin, 200 μg/ml streptomycin, and 2.5 μg/ml amphotericin B. Differentiation was induced by switching to differentiation medium which contained DMEM supplemented with 5% horse serum, 4 mM L-glutamine, 100 ng/ml insulin, and 0.1 μg/ml gentamicin. CgC was added at the same time as differentiation was initiated.

If not specified otherwise, treatment of cells with CgC or other small molecule compounds was performed as follows: stock solutions for each substance were prepared in a concentration of 20 mM, whereby the compounds were solved in DMSO. DMSO rather than water had to be used as solvent in order to guarantee sufficient solubility of all the compounds to be tested. The small molecule compounds were normally used in an end concentration of 1 μM. At this concentration, the cells were exposed to an amount of 0.005% DMSO. To provide comparable conditions, control cells, which did not obtain small molecule treatment, were always exposed to the same amount of DMSO (0.005%). A small molecule concentration of 1 μM was chosen for the experiments, because this concentration of CgC sufficed to induce significant cardiomyogenic effects in several different assays, whereas at the same time staying far away from concentrations which generate cellular toxicity (see [Fig. 5](#F5){ref-type="fig"}). Small molecule treatment lasted for 7 days, whereby fresh media were supplied twice during this time period. 7 day treatment duration was chosen, first, because C2C12 cells require about a week in differentiation medium in order to display mature electrophysiological properties \[[@R11]\]. Secondly, also in \[[@R9]\] and \[[@R12]\] CgC treatment durations of several days (4 days and 1 to 21 days, respectively) were used.

ANF and Nkx2.5 promoter luciferase reporter gene assays {#S8}
-------------------------------------------------------

For the ANF (atrial natriuretic factor) assay, a fragment containing the rat ANF promoter region was amplified and then subcloned into the PGL3-BV luciferase reporter plasmid \[[@R9]\]. The cells were transiently transfected with this plasmid (a kind gift from P.G. Schultz; The Scripps Research Institute, La Jolla, CA, USA), and with the pRL-SV40 Renilla luciferase control reporter vector (Promega). For transfections (always one day before start of small molecule treatment), lipofectamine plusTM Reagent (Invitrogen) was used according to the manufacturer's protocol. The expression of Renilla luciferase was used as an internal control for normalization of experimental variations such as differences in cell densities and transfection efficiencies. After 7 days of compound treatment (or 0.005% DMSO treatment of control cells), the cells were harvested, and luciferase activity was measured (Wallac 1420 Victor multilabel counter, Perkin Elmer) using Promega's dual-luciferase reporter assay kit according to the manufacturer's protocol. P19 cells treated with 10 nM all-trans retinoic acid for 7 days served as positive control for the assay. In this low concentration, retinoic acid drives cardiomyogenic differentiation in embryonic stem cells \[[@R13], [@R14]\]. For experiments to further test the cardiomyogenic activity of CgC, a Nkx2.5 promoter luciferase reporter plasmid (NKE24, Promega pGL3b plasmid (E1751) with an insert of the nkx2.5 promoter region) was used. The experimental procedure applied was identical to that described above for the ANF reporter gene assay.

Electrophysiological studies {#S9}
----------------------------

Sodium currents were recorded from differentiated spherically shaped C2C12 cells at room temperature (22 ± 1.5 °C) using an Axoclamp 200B patch-clamp amplifier (Axon Instruments, Union City, CA) as described previously \[[@R15]\]. Recording was begun 5 min after whole cell access was attained to minimize time-dependent shifts in gating. Pipettes were formed from aluminosilicate glass (AF150-100-10; Science Products, Hofheim, Germany) with a P-97 horizontal puller (Sutter Instruments, Novato, CA), heat-polished on a microforge (MF-830; Narishige, Tokyo, Japan), and had resistances between 1 and 2 MΩ when filled with the pipette solution (105 mM CsF, 10 mM NaCl, 10 mM EGTA, and 10 mM HEPES, pH 7.3). Voltage-clamp protocols and data acquisition were performed with pCLAMP 6.0 software (Axon Instruments) through a 12-bit analog-to-digital/digital-to-analog interface (Digidata 1200; Axon Instruments). Data were low-pass filtered at 2 kHz (−3 dB) and digitized at 10--20 kHz. Decay half time, a measure of fast inactivation kinetics, was obtained by analyzing the time period between the current peak and the time point at which the current had decayed to 50%. Slow inactivation was elicited by 10 s prepulses to various potentials (−100 mV to 0 mV) from a holding potential of −120 mV. Immediately thereafter, a 20 ms hyperpolarization period to −140 mV allowed the channels to recover from fast inactivation, before a 25 ms test pulse to −20 mV was applied to test for the fraction of slow inactivated channels. This fraction was determined by dividing the amplitude of the current elicited by the test pulse following a prepulse to 0 mV through the maximum current amplitude, and subsequent subtraction of the obtained value from 1. i.e. a calculated fraction value of 0.7 represents 70% slow inactivated and 30% slow inactivation-resistant channels. Sodium current density was calculated by dividing the maximum peak inward current amplitude (normally at −25 mV) of a cell by its membrane capacitance. To estimate the inhibition of sodium currents by tetrodotoxin (TTX), the TTX-resistant current fraction was detected. Recordings were made in a bathing solution that consisted of 140 mM NaCl, 2.5 mM KCl, 1 mM CaCl~2~, 1 mM MgCl~2~, and 10 mM HEPES, pH 7.4. Solution changes were performed with the use of a DAD-8-VC superfusion system (ALA Scientific Instruments, Westbury, NY).

Western blotting {#S10}
----------------

Western blot analyses were performed for detection of Na~v~1.5 sodium channel protein levels in control and CgC-treated C2C12 skeletal myoblasts. The cells were washed two times with ice-cold PBS before being shock-frozen in liquid nitrogen. Whole cell lysates were prepared with 100 μl immunprecipitation buffer added to each 6 cm dish, containing 25 mM Tris-HCl (pH=7.5), 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.1% Triton X-100 supplied with 1 mM PEFA-block, 10 μg/ml Leupeptin, and 2 μg/ml Aprotinin. The cell suspension was transferred to 1.5 ml Eppendorf tubes and incubated on ice for 30 minutes. During incubation time, the cell slurry was vortexed shortly (about 2 seconds) every 15 minutes. Lysates were ultra-sonicated for one minute and centrifuged at 15.000 rpm at 4 °C for 30 minutes. The supernatant was transferred to a new 1.5 ml tube. Protein concentration was determined for each sample by BioRad Quick Start Bradford Protein Assay, and 30 μg of protein from each sample was denaturated at 95 °C for 5 min, using sample buffer (15 mM Tris (pH=6.8), 3.6 mM Mercaptoethanol, 6.25% Glycerin, 0.5% SDS, 0.025% Bromphenol blue). The probes were resolved by SDS-PAGE using 7% separating gels and 5% collecting gels. Thereafter, proteins were transferred onto nitrocellulose membranes, blocked for 1 hour at room temperature with 5% BSA, and incubated at room temperature for 2 hours with the primary antibody against Na~v~1.5 (ASC-005, Alomone) at a dilution of 1 : 10000 solved in 2% BSA with 0.1% NaN~3~. Thereafter the secondary antibody (anti-rabbit IgG, Cell Signalling Technology, 7074) was applied in a dilution of 1 : 20000 (solved in 2% BSA) for 1 hour at room temperature. Protein bands were developed by GE Healthcare ECL Plus Western Blotting Detection Reagent following the manufacturer's protocol. The α-tubulin (antibody T6074, 1 : 10000, solved in 2% BSA with 0.1% NaN~3~, Sigma-Aldrich) signal was used as a loading control. The membranes were exposed on GE Healthcare ECL High performance chemiluminescence film, and the data was evaluated with densitometry (ImageJ software, Wayne Rasband National Institute of Health, USA).

Differentiation assays {#S11}
----------------------

For comparison of differentiation in untreated control and CgC-treated skeletal myoblasts, differentiation assays were performed similar as in \[[@R16]\]. Therefore, C2C12 cells were seeded at about 20% confluence in growth medium onto 3.5 cm dishes, and after 24 h, they were transferred to differentiation medium without (control) or with different concentrations of CgC (0.01 -- 10 μM). CgC treatment lasted for 7 days. Thereafter, cells were rinsed with PBS, fixed with 3.5% paraformaldehyde for 15 minutes at room temperature, washed three times (5 minutes each) with PBS, permeabilized with 0.1% Triton X-100 for 1 -- 4 min, and stained with the DNA dye SYBR Green (1:10000 diluted in PBS; S7563, Life Technologies) in order to visualize the nuclei. At 20-fold magnification, using a Zeiss LSM 510 confocal microscope, the cell margins were well visible (for example see [Fig. 3A](#F3){ref-type="fig"}, right). For each experiment, myotubes and nuclei were counted in five different areas (0.42 mm^2^ of size) per dish. Cells containing equal to or more than 3 nuclei were considered to represent differentiated myotubes as e.g. in \[[@R17]\].

Cardiac body experiments {#S12}
------------------------

The murine cardiovascular progenitor cell line A5 was originally isolated from newborn mouse hearts \[[@R18]\]. Cells were maintained on mitotically inactivated SNL76/7 fibroblasts and, after removal of the fibroblasts by adsorption, induced to differentiate by aggregation and formation of cardiac bodies (CBs) exactly as described \[[@R18]\]. Cardiomyogenesis was monitored under the light microscope in these CBs for 35 days, and the percentage of CBs with beating cardiomyocytes, and the number of beating clusters of cardiomyocytes per CB was determined. Clusters of beating cardiomyocytes are three-dimensional aggregates of physically connected cardiomyocytes, which contract rhythmically due to proper electromechanical coupling. Their number and size directly correlate with the extent of cardiomyogenic induction \[[@R18]\].

Toxicity assays {#S13}
---------------

For detecting a possible cellular toxicity of CgC, a colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed. This assay is based on the principle that only in living cells the yellow tetrazole MTT is reduced to purple formazan \[[@R19]\]. C2C12 cells were seeded in growth medium onto a 96 well plate (3000 cells per well), and after 24 hours, they were transferred to differentiation medium without (control) or with different concentrations of CgC (0.01 -- 100 μM). CgC treatment lasted for 7 days. Thereafter, the MTT assay reagent (EZ4U-E122, Biomedica) was added to the cells following the manufacturer's protocol. After the color change had occurred (1 -- 3.5 hours), the absorbance was measured (Wallac 1420 Victor multilabel counter, Perkin Elmer). The values obtained at the reference wavelength of 620 nm were subtracted from the values obtained at 450 nm. Absorbance from a substrate blank in assay medium without cells was subtracted from all other values. The resulting values correlate with the fraction of viable cells. The cytostatic agent vincristine (VC, 10 nM and 10 μM) served as a positive control harming the cells.

Statistics {#S14}
----------

If not otherwise specified data are expressed as means ± SEM. Statistical comparisons were carried out using two-tailed Student's t-tests (paired or unpaired as indicated). For comparison of more than two groups repeated measures ANOVA and Tukey's Post Hoc tests were performed. A p-value \< 0.05\* was considered significant; p \< 0.01\*\*, highly significant.

Chemical syntheses {#S15}
------------------

All compounds could be obtained using well established synthetic methods. CgC was derived as in \[[@R9]\]. The derivatives VUT-MK093, VUT-MK142, VUT-MK296, VUT-MK310, VUT-MK396, and VUT-MK431, were synthesized as reported in our previous paper \[[@R20]\]. VUT-MK092 was prepared in analogy to the procedure reported therein (for details see below). VUT-MK152 was synthesized via subsequent nucleophilic substitution reactions on 2,4-dichloropyrimidines. Initially the less reactive nucleophile, i.e. p-methoxyaniline was introduced in position 4. Subsequently, ethanolamine could be introduced in position 2 which required somewhat forced reaction conditions (see below). In VUT-MK465 and VUT-MK397 the aromatic amine was introduced via a Buchwald-Hartwig cross-coupling reaction \[[@R21], [@R22]\], followed by installing the aliphatic side chain again via a nucleophilic substitution reaction. All experimental procedures and analytical data can be found below.

Synthesis of VUT-MK465 {#S16}
----------------------

Step 1: Synthesis of 2-fluoro-*N*-(4-methoxyphenyl)pyridin-4-amine. 2-Fluoro-4-iodopyridine (50 mg, 0.22 mmol, 1 equiv), p-anisidine (33 mg, 0.27 mmol, 1.2 equiv), K~2~CO~3~ (108 mg, 0.78 mmol, 3.5 equiv), Pd(OAc)~2~ (1 mg, 0.004 mmol, 2 mol%), and BINAP (6 mg, 0.004 mmol, 2 mol%) were charged into a microwave vial and dry toluene (1mL) was added. The vial was then sealed, evacuated, and flushed with argon. Then the reaction mixture was irradiated at 180°C in a CEM Explorer™ microwave unit for 30 minutes with stirring. After cooling to r.t., the solid material was filtered off and washed with 10mL of CH2Cl2. The solvent was evaporated and the crude product was purified by column chromatography using PE: EtOAc = 2:1 giving 2-fluoro-*N*-(4-methoxyphenyl)pyridin-4-amine as yellow crystals in 63% (31 mg, 0.14 mmol) yield. mp: 150°C; TLC: R~f~ = 0.32 (PE:EtOAc = 2:1 ); GC-MS: 218 (M+, 79), 203 (100), 155 (13), 219 (11), 175 (10); ^1^H NMR (CDCl~3~, 200MHz): δ = 3.83 (s, 3H, --OCH~3~), 6.20 (d, J = 1.7 Hz, 1H, H5), 6.29-6.35 (bs, 1H, --NH), 6.51 (td, J~1~ = 5.9 Hz, J~2~ = 1.9 Hz, 1H, H3), 6.95 (d, J = 8.9 Hz, 2H, H3′), 7.14 (d, J = 8.8 Hz, 2H, H2′), 7.81 (d, J = 8.8 Hz, 1H, H6). ^13^C NMR (CDCl~3~, 50MHz): δ = 55.5 (t, -OCH~3~), 91.6 (q, J~C-F~ = 42.4 Hz, C3), 107.5 (q, J~C-F~ = 2.8 Hz, C5), 114.9 (d, C2′), 125.8 (d, C3′), 131.4 (s, C1′), 147.4 (q, J~C-F~ = 18.7 Hz, C6), 156.5 (d, J~C-F~ = 11.6Hz, C4), 157.6 (s, C4′), 165.5 (d, J~C-F~ = 232.7 Hz, C2). Combustion Analysis: Calculated: C 66.05% H 5.08% N 12.84%, Found: C 65.76% H 4.84% N 12.62%.

Step 2: Synthesis of 2-\[4-(4-methoxyphenylamino)pyridin-2-ylamino\]ethanol (VUT-MK465). 2-Fluoro-*N*-(4-methoxyphenyl)pyridin-4-amine (36 mg, 0.16 mmol, 1 equiv) was mixed with ethanolamine (80.6 equiv mg, 1.32 mmol, 8 equiv) and heated in a screw cap vial under argon at 150°C in a heating block for 3 days. After cooling to r.t. 2 N solution of NaOH (5 mL) was added and the mixture was extracted with EtOAc (15 mL) for three times. The EtOAc layer was then washed with brine and dried over Na~2~SO~4~. Evaporating the EtOAc layer gave pure VUT-MK465 as beige solid in 89% yield (38 mg, 0.15 mmol). mp: 164-165°C; TLC: R~f~ = 0.21(EtOAc: MeOH = 10:1); ^1^H NMR (DMSO-d~6~, 200MHz): δ = 3.22 (m, 2H, CH~2~), 3.45 (m, 2H, CH~2~), 3.72 (s, 3H, OCH~3~), 5.89 (s, 1H, NH), 6.05 (m, 2H, ArH, NH), 6.89 (d, J= 8.8 Hz, 2H, H2′ ), 7.07 (d, J= 8.8 Hz, 2H, H3′), 7.59 (d, J= 5.7 Hz, 1H, H3), 8.11 (s, 1H, H6); 13C NMR (DMSO-d~6~, 50MHz): δ = 43.8 (t, CH~2~), 55.2 (q, OCH~3~), 60.7 (t, CH~2~), 89.3 (d, C2′), 100.8 (d, C3′), 114.4 (d, C2), 122.9 (d, C3), 133.9 (s, C1′), 147.4 (d, C6), 151.9 (s, C4′), 154.9 (s, C4), 159.9 (s, C2); HR-MS: Predicted \[MH\]^+^= 260.1394; Measured \[MH\]^+^= 260.1400. Diff. in ppm= 2.31;

Synthesis of VUT-MK397 {#S17}
----------------------

Step 1: Synthesis of 6-chloro-*N*-(4-methoxyphenyl)pyridin-2-amine. 2,6-Dichloropyridine (100 mg, 0.68 mmol, 1 equiv,), p-anisidine (100 mg, 0.81 mmol, 1.2 equiv), K~2~CO~3~ (329 mg, 2.38 mmol, 3.5 equiv), Pd(OAc)~2~ (3 mg, 0.014 mmol, 2 mol%), and BINAP (9 mg, 0.014 mmol, 2 mol%) were charged into a microwave vial and dry toluene (2.5mL) was added. The vial was then sealed, evacuated and flushed with argon. Then the reaction mixture was irradiated at 180°C in a CEM Explorer™ microwave unit for 30 minutes with stirring. After cooling to r.t., the solid material was filtered off and washed with 10mL of CH~2~Cl~2~. The solvent was evaporated and the crude product was purified by column chromatography using PE: EtOAc = 4:3 to give 6-chloro-*N*-(4-methoxyphenyl)pyridin-2-amine as yellow solid in 72% yield (115 mg, 0.49 mmol). mp: 74-76°C; TLC: R~f~ = 0.41 (PE: CH~2~Cl~2~= 4:3); GC-MS: 219 (100), 234 (M+, 234), 221 (32), 112 (30), 233 (27); ^1^H NMR (CDCl~3~, 200MHz): δ = 3.81 (s, 3H, OCH~3~), 6.52 (d, J = 8.2 Hz, 1H, H5), 6.65 (d, J = 7.6 Hz, 1H, H3), 6.74 (s, 1H, NH), 6.89 (d, J =9.4 Hz, 2H, H3′), 7.19 (d, J =7.2 Hz, 2H, H2′), 7.34 (t, J = 7.9 Hz, 1H, H4). ^13^C NMR (CDCl~3~, 50MHz): δ = 54.6 (q, OCH3), 103.8 (d), 112.4 (d), 113.8 (d), 123.7 (d), 131.1 (s, C1′), 139.1 (d), 148.5 (s, C4′), 155.9 (s, C6), 156.4 (s, C2). Combustion Analysis: Cal. C 61.41%, H 4.72%, N 11.94%: Found C 61.42%, H 4.52%, N 11.78%.

Step 2: Synthesis of 3-\[6-(4-methoxyphenylamino)pyridin-2-ylamino\]propan-1-ol (VUT-MK397). 6-Chloro-*N*-(4-methoxyphenyl)pyridin-2-amine (95 mg, 0.41 mmol, 1 equiv) and propanolamine (244 mg, 3.25 mmol, 8 equiv) were mixed and heated in a screw cap vial under argon at 150°C in a heating block for 3 days. After cooling to r.t. water (5 mL) was added and the mixture was extracted with EtOAc (5 mL) for three times. The EtOAc layer was then washed with brine and then dried over Na~2~SO~4~. Evaporating the EtOAc layer gave the crude product. Pure VUT-MK397 was obtained by flash column chromatography (EtOAc) as colorless oil in 64% yield (72 mg, 0.26 mmol). TLC: R~f~ = 0.40 ( EtOAc ); ^1^H NMR (CDCl~3~, 200MHz): δ = 1.65-1.83 (m, 2H, CH~2~), 3.29 (t, J = 6.3 Hz, 2H, CH~2~), 3.64 (t, J = 5.8 Hz, 2H, CH~2~), 3.71 (s, 3H, OCH~3~), 5.72 (d, J = 8.2 Hz, 1H, ArH), 5.83 (d, J = 8.2, 1H, ArH), 8.79 (d, J = 8.9 Hz, 2H, H2′/H3′), 7.09 (d, J = 8.8 Hz, 2H, H2′/H3′), 7.18 (d, J = 8.02 Hz, 1H, ArH), 8.34 (s, 2H, NH). ^13^C NMR (CDCl~3~, 50MHz): δ = 31.8 (t, CH~2~), 38.8 (t, NCH~2~), 55.5 (q, OCH~3~), 59.2 (t, OCH~2~), 94.1 (d), 94.7 (s, C1′), 114.6 (d), 125.3 (d), 131.6 (s, C4′), 142.3 (s, C6), 153.9 (d), 155.2 (s, C2), 165.9 (d). HR-MS: Predicted \[MH\]^+^= 274.1550; Measured \[MH\]^+^= 274.1555. Diff in ppm= 1.82.

2-\[4-(4-Methoxyphenylamino)pyrimidin-2-ylamino\]ethanol (VUT-MK152) {#S18}
--------------------------------------------------------------------

2,4-Dichloropyrimidine (100 mg, 0.67 mmol, 1equiv), p-morpholino aniline (132 mg, 0.74 mmol, 1.1 equiv) and DIPEA (104.7 mg, 0.81 mmol, 1.2 equiv) were dissolved in EtOH (4 mL) at 0°C under nitrogen atmosphere and refluxed for 5h (4 mL). The crude product was filtered off and washed with cold EtOAc. This crude product (110 mg, 0.38 mmol, 1equiv) and ethanol amine (46.4 mg, 0.76mmol, 2eq) were charged into a microwave vial in n-BuOH (5 mL) and heated at 200°C for 30 minutes in microwave. After cooling to r.t., solvent (n-BuOH) was evaporated to give the crude product and excess of the amine. Purified product was obtained by crystallization from EtOH and n-BuOH solvent mixture as light yellow solid in 65% (110 mg, 0.35 mmol) yield. mp: 178-179°C; TLC: R~f~ = 0.13 (PE: EtOAc= 1:3); ^1^H NMR (CD~3~OD, 200MHz): δ = 3.09 (t, J = 4.8 Hz, 4H, 2NCH~2~), 3.47 (t, J = 5.6 Hz, 2H, NCH~2~), 3.70 (t, J = 5.6 Hz, 2H, OCH~2~), 3.83 (t, J = 4.8 Hz, 4H, 2OCH~2~), 5.96 (d, J = 5.9 Hz, 1H, H5), 6.95 (d, J = 9.2 Hz, 2H, H2′), 7.47 (d, J = 8.9 Hz, 2H, H3′), 7.71 (d, J = 5.9 Hz, 1H, H6). ^13^C NMR (CD3OD, 50MHz): δ = 44.8 (t, NCH~2~), 51.2 (t, morpholino-NCH~2~), 62.2 (t, OCH~2~), 68.1 (t, morpholino-OCH2), 97.3 (d, C5), 117.6 (d, C3′), 123.6 (d, C2′), 134.1 (s, C1′), 149.1 (s, C4′), 155.9 (d, C6), 163.0 (s, C4), 163.3 (s, C2). HR-MS: Predicted \[MH\]^+^= 275.1508; Measured \[MH\]^+^= 275.1498. Diff in ppm = 3.6

Synthesis of VUT-MK092 {#S19}
----------------------

Step 1: Synthesis of 6-chloro-*N*-(4-methoxyphenyl)pyrimidine-4-amine hydrochloride. 4,6-Dichloropyrimidine (1.57 g, 10.6 mmol, 1.3 equiv) and p-methoxyaniline (1g, 8.10 mmol, 1 equiv) were dissolved in *i*-PrOH (15 mL) and HCl (37%, 1.5mL) was added drop wise under N~2~ atmosphere. The reaction mixture was then refluxed (84°C) for 2.5 hour under nitrogen atmosphere. The reaction was monitored by TLC and was generally finished after 2.5 h. A precipitate appeared after cooling. The reaction mixture was then kept in the freezer overnight for complete precipitation. The colorless precipitate was filtered and washed with cold i-PrOH to get the pure product 6-chloro-*N*-(4-methoxyphenyl)pyrimidine-4-amine hydrochloride as colorless solid in 56% yield (1.60 g, 5.88 mmol). Mp: 121-123°C; TLC: R~f~= 0.85 (EtOAc: EtOH= 10:1); ^1^H NMR (DMSO-d~6~, 200MHz): δ = 3.75 (s, 3H, OCH3), 6.73 (s, 1H, H5), 6.95 (d, J = 8.8 Hz, 2H, H3′), 7.49 (d, J =8.8 Hz, 2H, H2′), 8.38 (s, 1H, H2), 9.89 (s, 1H, HCl). ^13^C NMR (DMSO-d~6~, 50MHz): δ = 55.3 (q, OCH~3~), 104.1 (d, C5), 114.1 (d, C3′), 122.6 (d, C2′), 131.6 (s, C1′), 155.7 (s, C4′), 157.1 (s, C6), 158.1 (d, C2), 161.3 (s, C4).

Step 2: Synthesis of 3-\[6-(4-methoxyphenylamino)pyrimidine-4-ylamino\]propan-1-ol (VUT-MK092). 6-Chloro-*N*-(4-methoxyphenyl)pyrimidine-4-amine hydrochloride (250 mg, 0.92 mmol, 1 equiv), propanolamine (75 mg, 1.0 mmol, 1.1 equiv), and DIPEA (296 mg, 2.29 mmol, 2.5 equiv) in *n*-BuOH (5 mL) were heated to 200°C for 45 minutes in a microwave. The crude product was obtained by evaporating n-BuOH. Crystallization from *n*-BuOH-EtOH solvent mixture gave the pure product VUT-MK092 as colorless solid in 85% yield (215 mg, 0.78 mmol). Mp: 151-152°C; TLC: R~f~ = 0.19 (EtOAc:EtOH= 10:1); ^1^H NMR (DMSO-d~6~, 200MHz): δ = 1.57-1.73 (m, 2H, CH~2~), 3.19 (q, J = 6.1 Hz, 2H, NCH~2~), 3.44 (q, J = 5.6 Hz, 2H, OCH~2~), 3.71 (s, 3H, OCH~3~), 4.48 (t, J = 5.2 Hz, 1H, NH), 5.62 (s, 1H, H5), 6.72 (t, J = 5.4 Hz, 1H, NH), 6.86 (d, J = 8.8 Hz, 2H, H3′), 7.35 (d, J =8.8 Hz, 2H, H2′), 8.11 (s, 1H, H2), 8.69 (s, 1H, OH). ^13^C NMR (DMSO-d~6~, 200MHz): δ = 32.6 (t, CH~2~), 37.5 (t, CH~2~), 55.3 (q, OCH~3~), 58.5 (t, CH~2~), 80.1 (d, C5), 114.1 (s, C1′), 122.0 (d, C3′), 133.4 (d, C2′), 154.5(s, C4′), 157.5 (d, C2), 160.5 (s, C4), 162.7 (s, C6). Combustion Analysis: Cal. C 61.30, H 6.61, N 19.42: Found C 61.17, H 6.67, N 19.39.

Results {#S20}
=======

CgC up-regulates the expression of the cardiac markers ANF and Nkx2.5 {#S21}
---------------------------------------------------------------------

CgC ([Fig. 1A](#F1){ref-type="fig"}) was previously shown to induce the expression of cardiac markers in pluripotent P19 embryonic carcinoma cells \[[@R9]\]. [Figure 1B](#F1){ref-type="fig"} shows that we could reproduce this finding by using a luciferase-based reporter gene assay. Thus, after treatment of P19 cells with 1 μM CgC for 7 days, the expression of atrial natriuretic factor (ANF, *nppa*) was significantly increased compared to untreated control cells. ANF is a commonly used cardiac marker gene. P19 cells treated with 10 nM retinoic acid for 7 days (positive control, five experiments) revealed 3.2 ± 0.6-fold luciferase activities compared with control cells. These experiments confirm the findings of \[[@R9]\], suggesting that CgC has a "cardiomyogenic effect" on P19 cells. To test if CgC does not only act cardiomyogenic on pluripotent embryonic stem cells, but also on a progenitor cell type that is already lineage-committed, we performed analogous ANF luciferase assay experiments on C2C12 skeletal myoblasts. This cell type has also previously been used for cardiomyogenic differentiation studies \[[@R23]-[@R25]\]. [Figure 1C](#F1){ref-type="fig"} (left) shows that, similar as in P19 cells, CgC treatment (1 μM, 7 days) significantly increased ANF expression in C2C12 cells. In addition, the expression of Nkx2.5, another frequently used cardiac marker gene (*NKX2-5*), was also increased by the small molecule ([Fig.1C](#F1){ref-type="fig"}, right).

Because our CgC-containing media comprised a low concentration of DMSO (0.005%), which, in higher concentrations (e.g. 0.5 - 1%), generates cardiomyogenic effects itself (e.g. \[[@R26], [@R27]\]), we performed control experiments. [Figure 1D](#F1){ref-type="fig"} shows that 7 day treatment of C2C12 cells with 0.005% or 0.05% DMSO failed to induce ANF expression. 0.5% DMSO, on the other hand, significantly increased ANF expression. These findings suggest that, in the CgC treatment studies described above ([Figs. 1B and C](#F1){ref-type="fig"}), the small molecule itself, but not DMSO, was causative for cardiac marker up-regulation.

In [Figure 1E](#F1){ref-type="fig"} we show that the cardiomyogenic effect of CgC on C2C12 cells is concentration-dependent. Thus, both ANF (top) and Nkx2.5 (bottom) expression were induced most by 100 μM CgC, the highest small molecule concentration used. Because of the cardiomyogenic effect of high concentrations of DMSO ([Fig. 1D](#F1){ref-type="fig"}), for these experiments, CgC was solved in water instead of DMSO.

Finally, auxiliary experiments suggested that CgC treatment of human skeletal myoblasts generated a similar increase in ANF expression as in C2C12 cells ([Fig. 1F](#F1){ref-type="fig"}).

Together these results suggest that CgC exerts cardiomyogenic effects on lineage-committed skeletal myoblasts.

CgC induces cardiac sodium currents in C2C12 skeletal myoblasts {#S22}
---------------------------------------------------------------

As an attempt to test if, in addition to cardiac marker up-regulation, CgC treatment also induces cardiac functional properties in lineage-committed cells, we compared voltage-gated sodium currents in control and CgC-treated C2C12 skeletal myoblasts. We chose to study sodium currents for the following reason: they exhibit distinct and well defined functional differences between skeletal and cardiac myocytes: first, sodium current fast inactivation kinetics is considerably slower in cardiomyocytes (e.g. \[[@R28]\]), and their sodium currents are more resistant to slow inactivation when compared to skeletal myocyte currents \[[@R29]\]. Secondly, the main cardiac sodium channel isoform Na~v~1.5 is resistant to block by tetrodotoxin (TTX), whereas skeletal muscle Na~v~1.4 channels are TTX-sensitive (e.g. \[[@R30]\]). Thus, from sodium currents, arising adaptations of their functional properties toward more cardiac-like ones can easily be judged. [Figure 2B](#F2){ref-type="fig"} shows that CgC treatment (1 μM, 7 days) significantly delayed the sodium current decay after channel activation in C2C12 cells. This suggests that this small molecule slows the sodium channel inactivation kinetics. In addition, CgC-treated cells showed a higher resistance towards slow inactivation than control cells. Thus, the fractions of slow inactivated channels (see Materials and Methods) amounted to 0.56 ± 0.04 (n=7) in CgC-treated, and 0.70 ± 0.05 (n=5) in control cells (p\<0.05; unpaired Student's t-test). The most straight forward explanation for these findings is that CgC treatment induces the expression of cardiac Na~v~1.5 channels in C2C12 cells. This was tested first by external application of 1 μM TTX (see [Fig. 2A](#F2){ref-type="fig"}), a concentration at which the toxin should almost completely eliminate skeletal muscle Na~v~1.4 channel currents, whereas only block about 50% of (TTX-resistant) cardiac Na~v~1.5 currents \[[@R30]\]. Indeed we found that, in CgC-treated C2C12 cells, the TTX-resistance of the sodium currents was significantly increased ([Fig. 2C](#F2){ref-type="fig"}, left) compared to that of control cells. In addition, the sodium current density, a measure for the number of functional channels in the cell membrane, was markedly increased by CgC treatment ([Fig. 2C](#F2){ref-type="fig"}, right). Together, these findings strongly suggest that CgC induces an up-regulation of the expression of the cardiac sodium channel isoform Na~v~1.5 versus the skeletal muscle isoform Na~v~1.4. To further confirm this hypothesis, western blot experiments were performed using a selective anti-Na~v~1.5 sodium channel antibody. [Figure 2D](#F2){ref-type="fig"} shows that CgC treatment (1 μM, 7 days) enhanced Na~v~1.5 protein levels in C2C12 cells. Thus, as suggested by the electrophysiological experiments described above, CgC upregulates the expression of the cardiac sodium channel isoform Na~v~1.5. Here it has to be mentioned that, besides Na~v~1.5, cardiomyocytes do also express skeletal muscle Na~v~1.4 and several other TTX-sensitive sodium channel isoforms (reviewed in \[[@R31]\]). These, however, are less abundantly expressed than Na~v~1.5, and therefore not considered in the present study.

Because it is well known that immature (in contrast to adult) skeletal myocytes share several properties with adult cardiomyocytes (e.g. the expression of cardiac protein isoforms such as cardiac myosin alkali light chains \[[@R32]\], cardiac troponin T \[[@R33]\], and the Na~v~1.5 sodium channel \[[@R34]\]) before they finally reach a mature differentiation state, we tested the effects of CgC on the differentiation of C2C12 cells. Thereby we wanted to exclude the possibility that CgC induces cardiac marker up-regulation and cardiac-like sodium currents simply by the inhibition of differentiation in these cells. [Figure 3A](#F3){ref-type="fig"} (left) shows that the morphology of control C2C12 cells after 7 days in differentiation medium was similar to that of CgC-treated cells. Moreover, both the numbers of nuclei per myotube ([Fig. 3B](#F3){ref-type="fig"}, left), and the numbers of myotubes per microscopic area ([Fig. 3B](#F3){ref-type="fig"}, right) - used as indicators for the differentiation state of the cells-were unaltered by CgC treatment. Together these experiments suggest that CgC does not inhibit C2C12 cell differentiation. Thus, cardiac marker up-regulation, and the induction of cardiac-like sodium currents in C2C12 skeletal myoblasts by this small molecule (see above) seem to be independent of inhibitory effects on differentiation.

CgC promotes the development of beating cardiomyocytes in cardiovascular progenitor cell-derived cardiac bodies {#S23}
---------------------------------------------------------------------------------------------------------------

In order to further characterize the potential of CgC to induce cardiomyogenic properties in lineage-committed progenitor cells, we switched to another cell type and approach. Thus, we studied if the small molecule increases the differentiation of murine A5 cardiovascular progenitor cells (CVPCs) to rhythmically contracting adult-like cardiomyocytes. A5 CVPCs, restricted to the cardiomyogenic lineage \[[@R18]\], were therefore aggregated, and cardiomyogenesis was monitored in cardiac bodies (CBs) for 35 days ([Fig. 4](#F4){ref-type="fig"}). Addition of 1 μM CgC from day 0 on significantly increased myocardial differentiation ([Fig. 4A and B](#F4){ref-type="fig"}) and resulted in a significantly increased percentage of CBs with beating cardiomyocytes ([Fig. 4B](#F4){ref-type="fig"}). Addition of CgC starting from the very beginning of cardiomyogenesis had a more pronounced effect than adding CgC only between days 5 and 7 ([Fig. 4C](#F4){ref-type="fig"}). In addition, the number of beating cardiomyocyte clusters was also increased especially when CgC was added from the very beginning of cardiomyogenesis ([Fig. 4D](#F4){ref-type="fig"}). This suggests that, besides exerting cardiomyogenic effects on C2C12 skeletal myoblasts, CgC also promotes the differentiation of CVPCs to contracting cardiomyocytes in a developmental stage-dependent manner. CgC seems to affect very early differentiation of CVPCs at a developmental stage long before any functional cardiomyocytes are formed on days 11 and later.

CgC concentrations up to 10 μM do not exert toxic effects on C2C12 cells {#S24}
------------------------------------------------------------------------

\[[@R9]\] reported that CgC showed significant toxicity on embryonic stem cells only at concentrations greater than 25 μM. Here we tested possible toxic effects of this small molecule on C2C12 cells by using MTT assays. [Figure 5](#F5){ref-type="fig"} shows that CgC concentrations up to 10 μM (7 day treatment) did not harm the cells. Only at the highest small molecule concentration used, 100 μM, significant cellular toxicity was observed. CgC either solved in water or DMSO generated a similar effect. We are aware that the use of MTT assays to determine the toxicity of a substance is limited by the fact that neither cellular function nor morphology is tested. This represents a limitation of the performed toxicity tests.

Structure variation of CgC leads to changes in cardiomyogenic activity {#S25}
----------------------------------------------------------------------

In order to determine structural characteristics of the small molecule CgC ([Fig. 1A](#F1){ref-type="fig"}) necessary for its cardiomyogenic activity, several derivatives of CgC ([Fig. 6](#F6){ref-type="fig"}) were synthesized. Thereafter, their cardiomyogenic activity was tested in ANF-luciferase reporter gene assays on C2C12 cells, the results of which are summarized in [Table 1](#T1){ref-type="table"}. It should be emphasized that the current investigation does not represent a comprehensive structure-activity relationship study, but rather a first step in this direction by changing key features of the molecule. A complete structure-activity relationship study would have been beyond the scope of this work, but is currently a main focus of follow-up studies within our laboratories, taking advantage of hypotheses based on the above observations when changing key structural features at the lead system.

Within a first generation of modifications, we did not employ any changes at the N-substituents (4-methoxyphenyl and --CH~2~CH~2~OH), and investigated the influence of the position and number of the ring nitrogens. Changing the substitution pattern at pyrimidine from 2,4 to 4,6 led to the CgC regioisomer VUT-MK093. In this case the activity in the ANF assay (2.0-fold compared to control, see [Table 1](#T1){ref-type="table"}) was higher compared to CgC (1.6). Subsequently, we investigated the influence of the ring nitrogens. Eliminating either N1 or N3 led to differently substituted pyridines. Eliminating N1 in CgC led to its 2,6 disubstiuted pyridine analog VUT-MK396. Interestingly, this compound showed similar activity as CgC in the ANF assay (1.7). On the other hand if N3 was eliminated, which led to the 2,4-disubstituted pyridine VUT-MK465, the activity was lost completely (1.0). Finally, the influence of N-substituents was investigated. Since 2,4-disubstituted pyrimidines were the topic of a previous report \[[@R9]\] we focused on structural modifications on 4,6-disubstituted pyrimidines and 2,6-disubstituted pyridines. Increasing the chain length of the aliphatic residue by one CH~2~ group led to a decreased activity as can be seen from the data for VUT-MK397 (pyridine, 0.7) and VUT-MK092 (pyrimidine, 1.2). Also the substituent in para position of the phenyl must not be too large. Switching from methoxy to phenoxy as in VUT-MK310 (0.9) led to an inactive compound. Some further derivatives of 4,6-disubstituted pyrimidines were prepared and tested for cardiomyogenic activity. Exchanging ethanolamine in VUT-MK093 for cyclohexylamine as in VUT-MK142 \[[@R20]\] led to the strongest activity in the ANF assay (2.3). Hence, the presence of the hydroxy group does not seem mandatory. This was confirmed by evaluating compound VUT-MK296 (1.6) which gave the same result as CgC ([Table 1](#T1){ref-type="table"}). However, a shorter alkyl chain seems to be detrimental for activity since VUT-MK431 was an inactive compound (1.2). Finally, a more severely changed structure was synthesized with VUT-MK152 ([Fig. 6](#F6){ref-type="fig"}). Here, the position of the ethanolamine substituent was changed from 4 to 2, and additionally a different aniline substituent was introduced in 4-position, which is significantly larger in size. Also this compound proved to be inactive, as VUT-MK152-treated C2C12 cells showed a similar activity in the ANF assay (1.2) as control cells (1.0).

Discussion {#S26}
==========

Synthetic small molecules are tools for potential use in regenerative medicine \[[@R35], [@R36]\]. Among their advantages are efficient delivery into cells, rapid activation or inhibition of targets, the reversibility of their effects, and the potential of modulating multiple molecular targets. These and other features qualify small molecules as promising agents for regenerative medicine developments. A feasible manner to increase the success of intra-cardiac cell transplantation therapy to regenerate the injured heart is the induction of cardiomyogenesis in donor cells prior to transplantation (e.g. \[[@R2], [@R3]\]). This goal could be achieved by treatment with cardiomyogenic small molecules \[[@R7]\].

Among several small molecules with cardiomyogenic effects \[[@R35]\], the cardiogenols \[[@R9]\], and in particular CgC, have shown promising activity. Thus, CgC induced embryonic stem cells to differentiate into spontaneously beating cardiomyocytes \[[@R9]\]. Whereas \[[@R26]\] could not confirm cardiomyogenic effects of CgC on P19 embryonic stem cells, \[[@R12]\] reported that this small molecule drives multipotent mouse hair bulge progenitor cells to transdifferentiate into cardiomyocyte-like cells. In the present study we show that CgC treatment enhances the expression of the classical cardiac marker ANF in P19 cells. Thereby we confirm the results of \[[@R9]\], suggesting that this small molecule has a cardiomyogenic effect on embryonic stem cells. More importantly, for the first time, here we provide evidence that CgC, besides acting on pluripotent embryonic stem cells, also exerts cardiomyogenic effects on already lineage-committed progenitor cell types such as skeletal myoblasts. This is remarkable because lineage-committed cells, compared to pluripotent embryonic stem cells, only show a limited cardiac differentiation potential, and the molecular signals required to induce cardiomyogenic differentiation in the various cell types may be different \[[@R37], [@R38]\]. Together with \[[@R9]\] and \[[@R12]\] our findings suggest that CgC exerts cardiomyogenic effects on a wide variety of cell types covering pluripotent embryonic and multipotent stem cells, as well as already lineage-committed progenitor cells. We therefore conclude that CgC is a small molecule with potent cardiomyogenic activity.

A noteworthy difference between CgC's cardiomyogenic effects on embryonic stem cells \[[@R9]\] and C2C12 skeletal myoblasts (present study) lies in the small molecule concentrations needed for activity. Thus, the EC~50~ value for the CgC effect on embryonic stem cells was 0.1 μM \[[@R9]\]. This small molecule concentration did not suffice for significant cardiac marker upregulation in C2C12 cells, but for this cell type considerably higher CgC concentrations were required ([Fig. 1E](#F1){ref-type="fig"}).

A significant weakness of the majority of published studies describing cardiomyogenic effects of small molecules on stem and/or progenitor cells lies in the circumstance that normally only cardiac marker up-regulation is taken as indicator for cardiomyogenesis. Cardiac marker expression in a cell alone, however, does not prove transdifferentiation into a real cardiomyocyte with specific cardiac-like functional properties. Above all, these attributes comprise appropriate electrical excitability and the ability to contract. In the present study we provide first evidence that, besides cardiac marker up-regulation in cells, CgC also induces cardiac functional properties: first, CgC treatment induced cardiac-like sodium currents in C2C12 skeletal myoblasts, and secondly, the small molecule promoted spontaneous contractions in cardiovascular progenitor cell-derived cardiac bodies. The exceptional importance of the induction of cardiomyogenic function in donor cells prior to intra-cardiac transplantation can be exemplarily outlined with reference to CgC's promotion of cardiac-like sodium current properties in skeletal myoblasts. A serious side effect observed after skeletal myoblast transplantation into the human heart are cardiac arrhythmias \[[@R1]\]. One conceivable reason therefore are the specific sodium channel properties in skeletal myoblasts, which differ from those in cardiomyocytes, and may disturb proper action potential conduction in the heart. In particular, in the heart, repetitive and long-lasting depolarizations are a normal feature of cardiomyocyte function. Under such conditions, Na~v~1.4 skeletal muscle sodium channels (in contrast to cardiac Na~v~1.5 channels) would undergo almost complete slow inactivation within a short time \[[@R29], [@R39]\]. Consequently, the strong likelihood of Na~v~1.4 sodium channels to enter the slow inactivated state, and their long-lasting recovery from this state, would impede repetitive firing of action potentials at a frequency of around 1 Hz \[[@R39]\], which is a prerequisite for the function of the human heart.

Taken together our data suggest that CgC induces cardiomyogenic function in addition to cardiac marker up-regulation in treated cells, and support the view that this small molecule is a potent cardiomyogenic agent.

At present very little is known about the molecular targets of CgC. \[[@R12]\] reported that the cardiomyogenic activity of CgC on mouse hair bulge progenitor cells involves activation of the Wnt signalling pathway and altered expression of several key chromatin remodelling proteins. Our lab has previously shown that the expression of cardiac Na~v~1.5 sodium channels in C2C12 skeletal myoblasts was significantly promoted by moderately rising intracellular calcium levels \[[@R15]\]. Since a similar effect, an up-regulation of Na~v~1.5 channel expression, is also observed in CgC-treated C2C12 cells (present study), it is tempting to speculate that this small molecule may at least partly act via calcium-dependent signalling mechanisms. As a next step to elucidate CgC's mechanism(s) of action, in the present study we determined essential structural characteristics of the small molecule necessary for cardiomyogenic activity. It seems that the presence of both nitrogens of the pyrimidine ring is beneficial for activity since from the five investigated pyridine derivatives (VUT-MK152, VUT-MK310, VUT-MK396, VUT-MK397, and VUT-MK465) only VUT-MK396 showed activity, whereas four out of seven pyrimidine derivatives were active (CgC, VUT-MK093, VUT-MK142, and VUTMK296). Also the position of the aliphatic and aromatic amine substituent on pyrimidine seems to be important. These positions were inverted in VUT-MK152 placing the aliphatic amine in position 2 and the aromatic amine in position 4, which led to an inactive compound. However, for this compound also the size of the aromatic amine was increased, which can also contribute to the inactivity of this compound. The same is true for the size of the aliphatic amine. It was shown that increasing the chain length from ethanolamine to propanolamine led to a significant drop in activity as in VUT-MK092 and VUT-MK397. The hydroxyl group, on the other hand, seems to be not mandatory since VUT-MK296 showed good activity still. If the aliphatic residue gets too small, activity is lost again as shown for VUT-MK431. Increasing the size of the aromatic amine was detrimental for activity as well (cf. VUT-MK152 and VUTMK310). Overall, these results indicate that not only the 1,3-relationship of the substituents is important, but also their size and the proper location on a pyrimidine scaffold.

We are currently carrying out experiments to identify the molecular targets of CgC.

Conclusions {#S27}
===========

Here we report that the small molecule compound CgC does not only act cardiomyogenic on pluripotent embryonic stem cells \[[@R9]\], but also on already lineage-committed progenitor cell types with a limited degree of plasticity. Moreover, for the first time, we show that this small molecule induces cardiac functional properties in cells in addition to cardiac marker up-regulation. Both our main findings suggest that CgC is a potent cardiomyogenic agent, and as such a promising tool to improve cardiac repair by cell transplantation therapy. In particular, treatment of adult and/or lineage-committed donor cell types with CgC prior to transplantation may be beneficial. Such cell types are considered safer for clinical use compared with embryonic stem cells, but do normally only show a very limited capacity to integrate into the host organ, and to trans-differentiate into functional cardiomyocytes after transplantation \[[@R1]\]. Treatment of the cells with potent cardiomyogenic agents, such as CgC, may help to overcome these problems, as previously suggested \[[@R7]\]. Another conceivable effect of CgC is the promotion of cardiac repair by the induction of cardiomyogenic differentiation in residual cardiovascular progenitor cells in situ. Finally, in the present study, we were also able to determine essential structural characteristics of the small molecule compound CgC necessary for its cardiomyogenic activity.

We would like to thank B. Gundacker for excellent technical assistance, and for keeping the laboratory of G.W. alive. We further thank M. Molin for technical assistance, and L. Weigl for providing the human skeletal myoblasts. P.G. Schultz is acknowledged for providing the plasmid used for the ANF luciferase reporter gene assay. We gratefully acknowledge financial support to this project via AWS (Uni:Invent Project Z090391). The work was also funded by the Austrian Science Fund (P19352 and P23060 to K.H.), and by two grants of the Hochschuljubiläumsstiftung der Stadt Wien (H1249/2009 and H2302/2011 to G.W.).

![Cardiogenol C (CgC) upregulates cardiac marker expression in C2C12 skeletal myoblasts. (A) Chemical structure of the small molecule compound CgC. (B) ANF luciferase reporter gene assay performed with control (CTL) and CgC-treated (1 μM, 7 days) P19 cells. Luciferase activity (in relative light units, RLU) from eight experiments is expressed as mean ± SEM normalized to the control. \* indicates a significant difference (p\<0.05) from the control (paired Student's t-test). (C) ANF (left) and Nkx2.5 (right) luciferase reporter gene assays performed with control (CTL) and CgC-treated (1 μM, 7 days) C2C12 cells. Number of experiments, 13 and 7, respectively. \* p\<0.05, and \*\* (p\<0.01) indicates a significant difference from the control (paired Student's t-test). (D) ANF luciferase reporter gene assay performed with untreated (UT) and DMSO-treated (0.005 -- 0.5%, 7 days) C2C12 cells. Luciferase activity (mean ± SEM) from 4 experiments (each in duplicates) was normalized to the untreated condition. ANOVA performed on the unnormalized raw data revealed a significant difference (p \< 0.01) between the 4 tested groups. \*\* indicates a significant difference (p\<0.01) to the untreated condition (Tukey's post hoc test). (E) ANF (top) and Nkx2.5 (bottom) luciferase reporter gene assays performed on C2C12 cells treated with different concentrations of CgC. Luciferase activity was normalized to the untreated condition. n values for the different CgC concentrations were 3 -- 7 for ANF, and each time 4 for Nkx2.5, respectively. For all these experiments water (instead of DMSO) was used as solvent for CgC. (F) ANF luciferase assay performed with control (CTL) and CgC-treated (1 μM, 7 days) human primary skeletal myoblasts. Number of experiments, 5. p = 0.11 (paired Student's t-test).](emss-59623-f0001){#F1}

![CgC induces cardiac-like sodium currents in C2C12 skeletal myoblasts. (A) Original traces of sodium currents in control C2C12 cells after 7 days in differentiation medium elicited by the pulse protocol shown on top. External application of 1 μM TTX reversibly reduced the current amplitudes. (B) Superimposed typical examples of current decay following activation by a voltage step from −120 to −30 mV of a control (empty circle) and CgC-treated cell (filled triangle) on an expanded time scale (left figure part). The intersections of the dashed line with the respective current traces indicate the time points at which the decay half times were determined. On the right, decay half times (means ± SEM), which represent the time period between the current peak and the time point at which the current had decayed to 50%, were plotted for control (CTL, n = 16) and CgC-treated (1 μM, 7 days) (n = 12) cells. \*\* indicates a significant difference (p\<0.01) from the control (unpaired Student's t-test). (C) Comparison of TTX-resistant sodium current fractions (left) and sodium current densities (right) in control (n = 16) and CgC-treated (n = 12) C2C12 cells. The TTX-resistant current fraction represents the relative residual current amplitude after equilibrium was reached following external application of 1 μM of TTX. \*\* (p\<0.01, unpaired Student's t-test). (D) Shown on top is a typical western blot experiment to compare cardiac Na~v~1.5 sodium channel protein levels between control C2C12 cells, and C2C12 cells which were treated with different concentrations of CgC. α-tubulin was used as a loading control. In the lower figure part, a results summary, obtained by densitometric analyses of seven such experiments (means ± SEM) (originating from 3 independent cell preparations and CgC treatment experiments), is displayed. ANOVA revealed a significant difference (p \< 0.01) between the tested groups. \* indicates a significant difference (p\<0.05) to the control (Tukey's post hoc test).](emss-59623-f0002){#F2}

![CgC does not influence differentiation of C2C12 skeletal myoblasts. (A) Microscopic images for comparison of the morphology of control (CTL) and CgC-treated C2C12 cells after 7 days in differentiation medium (left). On the right, differentiated control C2C12 cells at reduced cell density, treated with SYBR Green to visualize the nuclei, are displayed. Such images were used to count myotubes and nuclei for analyses of differentiation in control and CgC-treated cells. (B) The numbers of nuclei per myotube (left), and the numbers of myotubes per microscopic area (right) is compared between control C2C12 cells, and C2C12 cells which were treated with different concentrations of CgC. Three independent experiments were performed, and five different areas were considered per dish. Data represent means ± SEM.](emss-59623-f0003){#F3}

![Influence of CgC on cardiomyogenesis in cardiovascular progenitor cells. (A) *In vitro* development of cardiomyocytes from A5 cardiovascular progenitor cells aggregated to form cardiac bodies (CBs) in the absence (Control, empty circles) and presence of 1 μM CgC between day 0 and 13 (filled triangles). Number of experiments, 4. Data shown (% CBs with beating cardiomyocytes) are means of the values of a given day ± 1 day to get rid of the oscillation caused by the feeding protocol. Number of CBs monitored each, 80. All p values for data points between days 15 to 25 \< 0.01 (unpaired Student's t-test). (B) Extent of cardiomyogenesis expressed in arbitrary units normalized to the control. Data were derived from the experiments shown in A by calculating the fold increase over control for each day between days 14 to 24. The bar indicates the mean value ± standard deviation (STD) (p \< 0.01, unpaired Student's t-test). (C) Cardiomyogenesis in CBs when CgC was added either between days 0 and 5, or between days 5 and 7. Data (means ± STD) were sampled between days 12 and 20. Number of experiments, 4. (p\<0.01, unpaired Student's t-test). (D) Mean number of beating cardiomyocyte clusters per CB. Data (means ± STD) were sampled between days 14 and 17. Number of experiments, 2 (p\<0.01, unpaired Student's t-test).](emss-59623-f0004){#F4}

![CgC concentrations up to 10 μM do not exert toxic effects on C2C12 cells. MTT toxicity assays were performed on control and CgC-treated cells. CgC was either dissolved in water (left) or DMSO (right). Absorbance values (means ± SEM) were normalized to those of untreated cells (dashed line). Three independent experiments were performed, each of which in triplicates. The cytostatic agent vincristine (VC) served as a positive control. Independent of the CgC solvent (H~2~O, DMSO) used, ANOVA performed on the unnormalized raw data revealed a significant difference (p \< 0.01) between the tested groups. \*\* indicates a significant difference (p\<0.01) to the respective untreated condition (Tukey's post hoc test).](emss-59623-f0005){#F5}

![Depiction of the chemical structures of the small molecule compounds derived by structural modifications of CgC. Compounds VUT-MK 093, 142, 296, 310, 396, and 431 were already included in our previous study \[[@R20]\].](emss-59623-f0006){#F6}

###### 

ANF-luciferase activity values of small molecule-treated C2C12 cells expressed as fold increase over control. Data represent means ± SEM with the number of performed experiments (n) given in brackets.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  small molecule compound      CgC            [†](#TFN1){ref-type="table-fn"}VUT-\   VUT-\         [†](#TFN1){ref-type="table-fn"}VUT-\   VUT-\         [†](#TFN1){ref-type="table-fn"}VUT-\   [†](#TFN1){ref-type="table-fn"}VUT-\   [†](#TFN1){ref-type="table-fn"}VUT-\   VUT-\         [†](#TFN1){ref-type="table-fn"}VUT-\   VUT-\
                                              MK093                                  MK092         MK142                                  MK152         MK296                                  MK310                                  MK396                                  MK397         MK431                                  MK465
  ---------------------------- -------------- -------------------------------------- ------------- -------------------------------------- ------------- -------------------------------------- -------------------------------------- -------------------------------------- ------------- -------------------------------------- --------------
  normalized lucif. activity   1.6±0.1 (13)   2.0±0.6 (6)                            1.2±0.1 (5)   2.3±0.2 (10)                           1.2±0.1 (3)   1.6±0.2 (3)                            0.9±0.1 (3)                            1.7±0.1 (7)                            0.7±0.1 (3)   1.2±0.1 (4)                            1.0±0.03 (3)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

notifies CgC derivatives which were already included in our previous study \[[@R20]\]
